Noted scientist and owner of Medicinal Technologies Dr. Sheryene Tejeda MD PhD MHS MFS develops an unprecedented medical protocol for Endometriosis through The Tejeda Equation. Following decades of research and clinical trials, this internationally renowned doctor has made history with a revolutionary breakthrough for a disorder than has been proven effective for an array of other ailments. Valued at over $6 Billion dollars, the protocol is already being pursued for purchase by several of the largest pharmaceutical companies and elected for several awards. Endogen, not yet having been made available for purchase due to the influx of interest and manufacturing delays, is a three-part biomedical protocol reported to have no known serious adverse side effects and does not currently require a prescription. However, should it be purchased by one of the interested pharmaceutical companies, that will likely change. Endogen will initially be offered in the United States but soon will be purchasable regardless of a patient's location. It is anticipated that the medication will change the lives of many globally as according to statistics over 250 million women are diagnosed with Endometriosis, and millions more remain undiagnosed. To date there has been no viable remedy for the disease, which has caused women to seek relief through hormonal suppression, surgery and pain medications, all of which are temporary solutions of addressing the disease's symptoms, but none are remedies, and unfortunately some can cause further complications. Endogen however was created as a multi-faceted approach aimed at reversing the source of the disease. In addition to its benefits for Endometriosis, observations during clinical trials indicated promising results for the dissemination of cysts, fibroids, and other relative disorders that affect a woman's reproductive system.
Endometriosis is characterized by the abnormal presence and growth of endometrial tissues that if found outside of the uterine cavity. This disease that affects women of reproductive age involves a hormone-dependent inflammatory process that can occur during pre or post ovulation and heightened during a woman's menstrual cycle. Women experience varying levels of pain which can often times be debilitating. Heavy menstrual periods, scar tissue, inflammation, and abdominal pain. are some of the most common symptoms observed in women with Endometrial implants, The misplacement and continued growth of the tissue is known to cause reduced fertility, and various other medical issues, such as those within the digestive. Statistics support an increased rate of Irritable Bowel Syndrome in women who suffer from Endometriosis. which can be the result of taking certain pain medications for extended periods of time.
Women are frequently misdiagnosed with exaggerated premenstrual symptoms and consequently pay it little to no attention while the disease continues to progress. Ultimately, Endometriosis often results in minimized or the loss of fertility, an increased rate of intrauterine pregnancies pelvic and other complications as the endometrial lesions spread to other organs such as the bladder, bowel, rectum and ovaries. In some cases, it fuses organs together in conjunction with adhesions which is called having a frozen pelvis. Endometriosis is progressive in nature and is staged by a medical professional. Though its source of development has until now remain unknown; its prevalence globally was estimated for the past 30 years from diagnostic records and showed a total prevalence up to 71%. Such prevalence rates differ with respect to the diseases stage, however overall, it affects a woman's total well-being.
Dr. Tejeda's proposed mechanism of action for the development of Endometriosis (∑(σX GnRH ⇒ JEG3f )+ (σα ^βER ) ∴ NR3A1 ≥ 300-437pg/ml e (τ +30dy)∆ δEEC) involves the primary deviation in the GnRH gene, which is responsible for the production of gonadotropin-releasing hormone, a significant regulator of the female reproductive system. The Tejeda Equation is anticipated to change the course of medical history as it offers a never before observed correlation between a maternal monogenetic gene mutation and the development of Endometriosis.
Prior to the research findings of Dr. Tejeda, it was unknown if Endometriosis was a female medical condition, disorder, disease, or had genetic factors. Thanks to successfully conducted trials and research Dr. Tejeda asserts "we now know it is in fact a disease with epi genetic biomarkers".
* This is a contributed article and this content does not necessarily represent the views of sciencetimes.com
